The value of magnetic resonance imaging in the detection of prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels: A meta-analysis

Academic Radiology

Volumn 21, Issue 5, 2014, Pages 578-589

  Zhang, Zai Xian ^a   Yang, Jia ^a   Zhang, Cheng Zhong ^a   Li, Kang An ^a   Quan, Qi Meng ^a   Wang, Xi Fu ^a   Wang, Han ^a   Zhang, Gui Xiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Magnetic resonance imaging; Meta analysis; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; HUMAN; MAGNETIC RESONANCE IMAGING SPECTROSCOPY; MALE; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; T2 WEIGHTED IMAGING; TASK PERFORMANCE; AGED; BLOOD; LABORATORY DIAGNOSIS; META ANALYSIS; MIDDLE AGED; OBSERVER VARIATION; PROSTATIC NEOPLASMS; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA;

AGED; FALSE NEGATIVE REACTIONS; HUMANS; KALLIKREINS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSERVER VARIATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84897557524     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2014.01.004     Document Type: Article

References (43)

1. Center M.M., Jemal A., Lortet-Tieulent J., et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61(6):1079-1092.
2. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
3. Wolf A.M., Wender R.C., Etzioni R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60(2):70-98.
4. Haas G.P., Delongchamps N., Brawley O.W., et al. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 2008, 15(1):3866-3871.
5. Aigner F., Pallwein L., Junker D., et al. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25 ng/ml or greater and 4.00 ng/ml or less. J Urol 2010, 184(3):913-917.
6. Eichler K., Hempel S., Wilby J., et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006, 175(5):1605-1612.
7. Luciani L.G., De Giorgi G., Valotto C., et al. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings. Urology 2006, 67(3):555-558.
8. Finne P., Auvinen A., Maattanen L., et al. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol 2008, 54(2):362-370.
9. Pondman K.M., Futterer J.J., ten Haken B., et al. MR-guided biopsy of the prostate: an overview of techniques and a systematic review. Eur Urol 2008, 54(3):517-527.
10. Tempany C., Straus S., Hata N., et al. MR-guided prostate interventions. J Magn Reson Imaging 2008, 27(2):356-367.
11. Schouten M.G., Bomers J.G., Yakar D., et al. Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies. Eur Radiol 2012, 22(2):476-483.
12. Hambrock T., Hoeks C., Hulsbergen-van de Kaa C., et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012, 61(1):177-184.
13. Sciarra A., Panebianco V., Ciccariello M., et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clinical cancer research 2010, 16(6):1875-1883.
14. Cirillo S., Petracchini M., Della Monica P., et al. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin Radiol 2008, 63(8):871-879.
15. Prando A., Kurhanewicz J., Borges A.P., et al. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 2005, 236(3):903-910.
16. Michael Seitz A.S.-D., Bjartell A., et al. Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009, 55(4):801-814.
17. Whiting P., Rutjes A.W., Reitsma J.B., et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003, 3:25.
18. Harbord R.M., Deeks J.J., Egger M., et al. A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 2007, 8(2):239-251.
19. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
20. Zamora J., Abraira V., Muriel A., et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
21. Perrotti M., Han K.R., Epstein R.E., et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: a pilot study. J Urol 1999, 162(4):1314-1317.
22. Beyersdorff D., Taupitz M., Winkelmann B., et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002, 224(3):701-706.
23. Yuen J.S.P., Thng C.H., Tan P.H., et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 2004, 171(4):1482-1486.
24. Amsellem-Ouazana D., Younes P., Conquy S., et al. Negative prostatic biopsies in patients with a high risk of prostate cancer: is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol 2005, 47(5):582-586.
25. Bhatia C., Phongkitkarun S., Booranapitaksonti D., et al. Diagnostic accuracy of MRI/MRSI for patients with persistently high PSA levels and negative TRUS-guided biopsy results. J Med Assoc Thai 2007, 90(7):1391-1399.
26. Portalez D., Rollin G., Leandri P., et al. Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur Radiol 2010, 20(12):2781-2790.
27. Testa C., Schiavina R., Lodi R., et al. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed 2010, 23(9):1017-1026.
28. Panebianco V., Sciarra A., De Berardinis E., et al. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations. Anticancer Res 2011, 31(4):1399-1405.
29. Scheidler J., Weres I., Brinkschmidt C., et al. Diagnosis of prostate cancer in patients with persistently elevated PSA and tumor-negative biopsy in ambulatory care: Performance of MR imaging in a multi-reader environment. Fortschr Röntgenstr 2012, 184(2):130-135.
30. Girometti R., Bazzocchi M., Como G., et al. Negative predictive value for cancer in patients with "gray-zone" PSA level and prior negative biopsy: preliminary results with multiparametric 3.0 Tesla MR. J Magn Reson Imaging 2012, 36(4):943-950.
31. Costa D.N., Bloch B.N., Yao D.F., et al. Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies. Magn Reson Imaging 2013, 31(6):947-952.
32. Roehl K.A., Antenor J.A., Catalona W.J. Serial biopsy results in prostate cancer screening study. J Urol 2002, 167(6):2435-2439.
33. Scattoni V., Zlotta A., Montironi R., et al. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007, 52(5):1309-1322.
34. Ashley R.A., Inman B.A., Routh J.C., et al. Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol 2008, 53(5):976-981.
35. Taira A.V., Merrick G.S., Galbreath R.W., et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis 2010, 13(1):71-77.
36. Merrick G.S., Taubenslag W., Andreini H., et al. The morbidity of transperineal template-guided prostate mapping biopsy. BJU Int 2008, 101(12):1524-1529.
37. Barzell W.E., Melamed M.R., Cathcart P., et al. Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol 2012, 188(3):762-767.
38. Kumar V., Jagannathan N.R., Kumar R., et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed 2007, 20(1):11-20.
39. Lawrentschuk N., Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009, 103(6):730-733.
40. Glas A.S., Lijmer J.G., Prins M.H., et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003, 56(11):1129-1135.
41. Moore C.M., Robertson N.L., Arsanious N., et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013, 63(1):125-140.
42. Weinreb J.C., Blume J.D., Coakley F.V., et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009, 251(1):122-133.
43. Song F., Khan K.S., Dinnes J., et al. Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 2002, 31(1):88-95.